We are now in a scientific era where advances in basic understanding of cellular behaviour and technological breakthroughs are opening new and exciting avenues in cancer research and clinical management of patients with malignant disease. One such advancement is the development of monoclonal antibodies (Kohler & Milstein, 1975) . Like many other 'breakthroughs' in biomedical research, monoclonal antibodies have been through the three phases of maturation. At the beginning, there was the excitement and hype that not only would monoclonal antibodies revolutionise the diagnosis, but they would also cure many, if not most, so far incurable cancers. In fact, early pilot studies had suggested that this could be the case in both diagnosis (Mach et al., 1981; Epenetos et al., 1982a; Farrands et al., 1982) and therapy (Sears et al., 1982; Miller et al., 1982) . Unfortunately this euphoria was short lived because subsequent and more comprehensive studies ) demonstrated a major fundamental problem with antibody targeting. That was, that after intravenous administration of monoclonal antibodies in patients, only a very small proportion of the injectate localised to tumour sites (-0.005% of the injected amount per gram of tumour) which is approximately 100-1,000 times less than when the same antibody is tested in animal models, e.g. nude mice bearing human cancer xenografts (Epenetos et al., 1982b; Schlom, 1986) . These small amounts of antibodies are hardly sufficient to allow successful imaging of small lesions undiagnosed by existing conventional radiological techniques and are certainly not sufficient to deliver tumoricidal amounts of cytotoxic agents to tumour cells without damaging other normal organs such as the bone marrow, liver and kidneys.
So what is the state of the art with monoclonal antibodies today? It is the author's opinion that we have now entered the third and, it is hoped, final phase of maturity, which is understanding the shortcomings of monoclonal antibodies and designing methods to overcome them. To understand the mechanism of antibody targeting to tumour tissues in vivo, at least two aspects need to be considered.
The first is the host handling of the antibody, which includes both normal and neoplastic tissues. After an antibody is injected into the blood stream the following events happen before it can reach the tumour cells (Jain, 1987) : the antibody is diluted by the vascular volume; transported across microvessel endothelial cells; enters normal and neoplastic interstitium and binds on to specific antigens and possible internalisation.
Data available so far (Jain, 1987) indicate that the interstitial space of neoplastic tissues differs significantly from that of normal tissues both in structure and function. In general, tumours have high interstitial fluid pressure and fluid flow, probably due to the fact that their interstitial spaces are larger than normal and lack a functioning lymphatic system. This may be an advantage in using monoclonal antibodies for tumour targeting because a high intratumoral interstitial fluid pressure and flow may allow for more efficient interstitial diffusion of macromolecules Correspondence: A.A. Epenetos. such as antibodies. On the other hand, in large tumours high interstitial pressure and low microvessel pressure may slow down the extravasation of antibodies into tumour tissues. Of course, before an antibody reaches the interstitium of tumours it may be catabolised. Immunoglobulin catabolism is carried out by the reticuloendothelial system and the liver in particular, where both parenchymal and non-parenchymal cells are involved (Sands et al., 1989) .
The second aspect is the characteristics of individual monoclonal antibodies and their conjugates. Monoclonal antibodies, like all antibodies, consist of the minimum essential part required to bind antigen, i.e. the antigen binding loops of the V domains coded by the complementarity determining regions (CDRs) of the V genes and the rest of the V domains as well as constant regions of heavy and light immunoglobulin chains.
The exquisite specificity of monoclonal antibodies for their targets is determined by the 3-D structure of the V domain and CDR loops. The presence of tumour associated or tumour 'specific' antigens is an essential prerequisite for successful tumour targeting using antibodies. It is not the purpose of this article to review human tumour antigens but, rather, to focus on a few interesting examples which may prove useful in our selection of antigen-antibody systems.
Human milk fat globule membrane
A highly immunogenic component of the human milk fat globule membrane is a large molecular weight mucin (>400kD) which is also secreted into milk (Ceriani et al., 1982) . A large number of tumour associated antigens defined by existing monoclonal antibodies are carried out on molecules that are immunologically related or identical to the milk mucins (Taylor-Papadimitriou et al., 1981; Arklie et al., 1981) . Some tumour mucins are aberrantly or incompletely glycosylated, allowing for their protein core to be exposed. This observation has been exploited and new monoclonal antibodies directed against protein core components of tumour mucins have been produced Gendler et al., 1987) . Antibodies such as these, reacting with protein determinants which are only exposed in tumours, can be described as 'operationally tumour specific'.
In fact, from the vast pool of existing antitumour monoclonal antibodies, there exists a small group of antibodies directed against unique epitopes of antigens that allow for increased tumour specificity. These include the SM3 Gendler et al., 1987) against an epitope of stripped mucin and found widely on carcinomas, B72.3 (Hand et al., 1985) against a glycoprotein on many tumours and OVTL3 (Poels et al., 1986) and MOV 18 (Miotti et al., 1987) Group, 1985; Begent, 1989) . The second approach is to try and induce specific unresponsiveness to rodent immunoglobulins by the use of immunosuppressive antibodies (Benjamin & Waldmann, 1986) or by coupling substances such as polyethylene glycol, which apparently may convert xenogeneic monoclonal antibodies to specific tolerogens (Sehon, 1989) . A third way is to use human monoclonal antibodies produced from EpsteinBarr virus transformed human b-lymphocytes or from human or human mouse hybridomas (Sikora et al., 1982; Cote et al., 1983) . This approach has only had limited success so far but a new technique exploiting the immunological idiotypic network (Ritter et al., 1987) (Wahl et al., 1983) . Fragments produce faster and better tumour to non-tumour ratios because they are cleared more rapidly from the circulation and there is less non-specific uptake by Fc binding cells or carbohydrate catabolising cells (Sands et al., 1989) . A recent development has been the recombinant production of Fv fragments. These are the smallest possible intact fragments of the antibody molecule that can bind antigen in the appropriate configuration (Verhoeyen et al., 1988 A second possibility to increase tumour uptake of antibody is to give a much higher amount of antibody as long as this is relatively non-toxic to the host. It would be advantageous if the cytotoxic moeity or imaging isotope could then be delivered at a time when the tumour to nontumour ratios are optimal and at a time when there was no significant circulating amount of antibody. Consideration of the difficulties of delivering adequate quantities of antibody has resulted in several current lines of research. Hybrid antibodies with dual specificities can be produced by the cell fusion of two Ig producing cell lines (Milstein & Guello, 1983; Clark & Waldmann, 1989) or by chemically conjugating two monomeric Fab fragments (Perez et al., 1985) . Hybrid antibody may be capable of targeting diagnostic or therapeutic radioisotopes such as indium-ill and yttrium-90 (Goodwin, 1987) or targeting drug (Corvalan et al., 1988) or toxins (Webb et al., 1985) to cells expressing appropriate cell surface antigens. Of greater interest, perhaps, may be the ability of these bispecific antibodies to induce potent tumour cell killing by activated T-cells if the bispecific antibody can cross-link T-cells and antigens on the surface of tumour cells (Clark & Waldman, 1989; Canevari et al., 1988) .
Another novel approach is the in vivo use of streptavidin conjugated antibodies followed, after an appropriate period of time, by radioactive biotin either for imaging or therapy. Biotin has an extremely high affinity for streptavidin (Dd =15 M-10) and at the same time is a small enough molecule that can diffuse rapidly through most tissues in the body. Using, initially, experimental models (Hnatowich et al., 1987; Paganelli et al., 1988) and more recently clinical studies (Hnatowich et al., 1989) it has been shown that the tumour target to non-target ratios may be improved considerably.
A different and rather interesting strategy has recently been proposed by Professor K. Bagshawe and his colleagues, who used a two-step approach (Bagshawe et al., 1989) . In their system a prodrug is activated at the tumour site by a nonmammalian enzyme conjugated on to antibody. As the first step, the antibody-enzyme conjugate is injected and allowed to localise to tumours. After a certain period of time, it is followed by a prodrug which diffuses readily through tissues. This prodrug is relatively stable and only gets activated by the targeted enzyme on tumour sites. The prodrug becomes a highly toxic agent which can enter tumour cells and at the same time has a short half-life so that it is of low toxicity to normal tissues (Bagshawe et al., 1989) .
We have already acknowledged the difficulties resulting from the immunogenicity of rodent monoclonal antibodies when injected repeatedly into humans. This problem may be reduced but may not be totally eliminated even if one could use human monoclonal antibodies because of the possibility of developing anti-idiotypic and anti-allotypic antibodies (Ritter et al., 1987) . Can one, however, use this phenomenon to the patient's advantage? It has been shown by several workers (Schroff et al., 1985; Courtenay-Luck et al., 1986; Ritter et al., 1987) that antigen antibody response developing in recipients is partly directed against the variable region (idiotype) of the administered antibody (anti-id1 response). Some of these anti-idiotypic antibodies are directed against the combining site (paratope) of the administered monoclonal antibody and therefore represent an 'internal image' of the tumour antigen. In some cases, this can lead to a marked elevation of human serum antibodies that themselves bind to tumour antigen, with a specificity similar to that of the injected antibody. These are now human anti-tumour antibodies which may mediate a cytotoxic response. The discovery of anti-idiotypic antibodies has led to the proposal of making idiotypic vaccines in cases where purified tumour antigen is not available or is presented to the immune system in a non-immunogenic way. In fact animal studies using tumour specific idiotypic vaccines have produced encouraging results (Dunn et al., 1987; Raychaudhari et al., 1987) . Therefore, the effects of generating anti-idiotypic responses may not necessarily be detrimental to the host. It may be possible to switch on such a response to the patient's advantage once we know how to manipulate the idiotypic network (Jerne, 1971) and provide the patient with autoanti-tumour antibodies.
Some new concepts such as new tumour targets, recombinant antibodies and fragments, two-step strategies and exploitation of the idiotypic network have been briefly reviewed. In addition, there has been a great deal of progress in the basic chemistry of immunoconjugates providing increased stability and retention of immunoreactivity in antibody-drug conjugates (Kanellos et al., 1985) , immunotoxins (Thorpe et al., 1987) , antibody-isotopes (Moi et al., 1985; Gansow et al., 1989; Eaton et al., 1989; Abrams et al., 1989) and site specific radiolabelling (Rodwell et al., 1986 
